BrightFocus Foundation’s 2026 Annual Report highlights cutting-edge research and public awareness across Alzheimer's disease, macular degeneration, and glaucoma.
Written By: BrightFocus Editorial Staff
BrightFocus Foundation’s 2026 Annual Report highlights the impact of donor support in advancing research to defeat Alzheimer’s disease, macular degeneration, and glaucoma and empowering those affected by these diseases with expert resources and information.
In 2025-26, BrightFocus supported 182 active research grants across 17 countries, accelerating discoveries that could lead to earlier detection methods, more effective treatments, and, ultimately, cures.
In this year’s Annual Report:
Read the annual report in magazine format or view a printable format (PDF).
BrightFocus Foundation is a premier global nonprofit funder of research to defeat Alzheimer’s, macular degeneration, and glaucoma. Since its inception more than 50 years ago, BrightFocus and its flagship research programs—Alzheimer’s Disease Research, Macular Degeneration Research, and National Glaucoma Research—has awarded more than $330 million in research grants to scientists around the world, catalyzing thousands of scientific breakthroughs, life-enhancing treatments, and diagnostic tools. We also share the latest research findings, expert information, and resources to empower the millions impacted by these devastating diseases. Learn more at brightfocus.org.
Disclaimer: The information provided here is a public service of BrightFocus Foundation and is not intended to constitute medical advice. Please consult your physician for personalized medical, dietary, and/or exercise advice. Any medications or supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical products or therapies.
A new campaign launched during World Alzheimer’s Month features renowned actor, producer, and writer Andre Royo, who lost his mother, Andrea Royo, to Alzheimer’s disease in 2024.
With a 2025 impact factor of 19.6 and a No. 5 ranking among 330 neuroscience journals worldwide, Molecular Neurodegeneration continues to expand its influence on research into Alzheimer’s disease, macular degeneration, glaucoma, and related neurodegenerative disorders.
A pioneering clinician-scientist at Memorial Sloan Kettering Cancer Center, Dr. Abramson has transformed understanding and treatment of eye cancers worldwide.
At a ceremony recognizing 2026 vision grant recipients, these prestigious awards honor five standout scientists whose work is shaping the future of prevention, treatments, and cures for macular degeneration and glaucoma—two leading causes of vision loss.
Donate Now to Fund Critical Research
Your gift today can help drive innovation in Alzheimer's, macular degeneration, and glaucoma research. By donating, you’ll support life-changing research and provide valuable resources for those affected by these devastating diseases. Give now to fuel hope and bring us closer to finding cures.
